Phase I study of Erlotinib and Crizotinib after ALK inhibitor failure in ALK positive advanced Non-Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2019
At a glance
- Drugs Crizotinib (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 26 Feb 2019 Status changed from active, no longer recruiting to discontinued.
- 14 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 22 Feb 2013 New trial record